Certainly, the data in Foster et al. challenge us to consider the potential application of BBB permeant pharmacological interventions, especially early in the HF disease process, to inhibit AT1 receptor- and βAR-stimulated ventilatory overdrive and mitigate diaphragmatic myopathy. This evidence concerns the gene ADRB2 and hydrops fetalis.